LIVIVO - Search results -

Search results

Result 1 - 10 of total 22

Search options

Article: Cardiac defects of hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders: a retrospective cohort study.

Knight, Dacre R T / Bruno, Katelyn A / Singh, Ayush / Munipalli, Bala / Gajarawala, Shilpa / Solomon, Mahima / Kocsis, S Christian / Darakjian, Ashley A / Jain, Angita / Whelan, Emily R / Kotha, Archana / Gorelov, David J / Phillips, Sabrina D / Fairweather, DeLisa

Frontiers in cardiovascular medicine

2024 Volume 11, Page(s) 1332508

Abstract: Background: Defective connective tissue structure may cause individuals with hypermobile Ehlers-Danlos syndrome (hEDS) or hypermobility spectrum disorders (HSD) to develop cardiac defects.: Methods: We conducted a retrospective chart review of adult ... ...

Abstract	Background: Defective connective tissue structure may cause individuals with hypermobile Ehlers-Danlos syndrome (hEDS) or hypermobility spectrum disorders (HSD) to develop cardiac defects. Methods: We conducted a retrospective chart review of adult patients treated in the EDS Clinic from November 1, 2019, to June 20, 2022 to identify those with cardiac defects. Echocardiogram data were collected using a data collection service. All EDS Clinic patients were evaluated by a single physician and diagnosed according to the 2017 EDS diagnostic criteria. Patient demographic, family and cardiac history were extracted from self-reported responses from a REDCap clinical intake questionnaire. Patients with at least 1 available echocardiogram (ECHO) were selected for the study ( Results: The prevalence of aortic root dilation in patients with hEDS was 2.7% and for HSD was 0.6%, with larger measurements for males than females and with age. Based on self-reported cardiac history that was verified from the medical record, patients with hEDS with bradycardia ( Conclusions: These data reveal a low prevalence of cardiac defects in a large cohort of well-characterized hEDS and HSD patients. Differences in cardiovascular issues were not observed between patients with hEDS vs. HSD; and our findings suggest that cardiac defects in patients with hEDS or HSD are similar to the general population.
Language	English
Publishing date	2024-03-18
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2781496-8
ISSN	2297-055X
ISSN	2297-055X
DOI	10.3389/fcvm.2024.1332508
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Laryngological Complaint Prevalence in Hypermobile Ehlers-Danlos or Hypermobility Spectrum Disorders.

Menton, Stacey M / Fairweather, DeLisa / Bruno, Katelyn A / Thompson, Chandler C / Candelo, Estephania / Darakjian, Ashley A / Gehin, Jessica M / Jain, Angita / Kotha, Archana / Whelan, Emily R / Li, Zhuo / Knight, Dacre R T / Rutt, Amy L

The Laryngoscope

2023 Volume 134, Issue 2, Page(s) 773–778

Abstract: Objective: The aim was to study laryngological complaints in patients with hypermobile Ehlers-Danlos syndrome (hEDS) or hypermobility spectrum disorders (HSD).: Methods: A total of 363 patients met inclusion for the study by completing questions ... ...

Abstract	Objective: The aim was to study laryngological complaints in patients with hypermobile Ehlers-Danlos syndrome (hEDS) or hypermobility spectrum disorders (HSD). Methods: A total of 363 patients met inclusion for the study by completing questions related to voice, upper airway, and swallowing between July 7, 2020 and July 13, 2022. Demographic data, voice-related questions, and hypermobility diagnosis were analyzed retrospectively. From those, 289 patients were diagnosed with hEDS or HSD with 74 that did not meet the diagnostic criteria for either diagnosis serving as controls. Results: There were no statistically significant differences between patients with hEDS and HSD regarding Voice Handicap Index (VHI-10) scores, voice, upper airway, or swallow complaints. However, more hEDS/HSD patients answered positively to the laryngeal dysfunction question versus controls (p = 0.031). 22.5% of hEDS/HSD patients (n = 65) reported hoarseness, of which 52.3% reported hoarseness >2 days/month. 33.9% (n = 98) with hEDS/HSD reported symptoms of dysphagia, and 27.0% (n = 78) reported laryngeal dysfunction symptoms. Controls demonstrated 20.3% prevalence of hoarseness, of which 46.7% reported hoarseness >2 days/month. 24.3% of controls had dysphagia and 14.9% laryngeal dysfunction symptoms. Of the 363 patients, VHI-10 scores >11 were more likely in patients reporting >2 days of hoarseness/month (p = 0.001) versus those with <2 days of hoarseness/month. There was an increased prevalence of voice, upper airway, and dysphagia symptoms in hEDS/HSD patients compared with previously reported prevalence data in the general population. Conclusion: A significant proportion of patients diagnosed with hypermobility due to hEDS or HSD were found to have voice, upper airway, and dysphagia symptoms. These rates are higher than those previously reported in the general population. Level of evidence: 3 Laryngoscope, 134:773-778, 2024.
MeSH term(s)	Humans ; Prevalence ; Hoarseness ; Deglutition Disorders/epidemiology ; Deglutition Disorders/etiology ; Retrospective Studies ; Joint Instability/epidemiology ; Joint Instability/diagnosis ; Ehlers-Danlos Syndrome/complications ; Ehlers-Danlos Syndrome/epidemiology ; Ehlers-Danlos Syndrome/diagnosis
Language	English
Publishing date	2023-08-19
Publishing country	United States
Document type	Journal Article
ZDB-ID	80180-x
ISSN	1531-4995 ; 0023-852X
ISSN (online)	1531-4995
ISSN	0023-852X
DOI	10.1002/lary.30964
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ul II Zs.82: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Upregulation of Endothelin-1 May Predict Chemotherapy-Induced Cardiotoxicity in Women with Breast Cancer.

Krishnarao, Krithika / Bruno, Katelyn A / Di Florio, Damian N / Edenfield, Brandy H / Whelan, Emily R / Macomb, Logan P / McGuire, Molly M / Hill, Anneliese R / Ray, Jordan C / Cornell, Lauren F / Tan, Winston / Geiger, Xochiquetzal J / Salomon, Gary R / Douglass, Erika J / Fairweather, DeLisa / Yamani, Mohamad H

Journal of clinical medicine

2022 Volume 11, Issue 12

Abstract: As survival in breast cancer patients from newer therapies increases, concerns for chemotherapy-induced cardiotoxicity (CIC) have offset some of these benefits, manifesting as a decline in left ventricular ejection fraction (LVEF). Patients receiving ... ...

Abstract	As survival in breast cancer patients from newer therapies increases, concerns for chemotherapy-induced cardiotoxicity (CIC) have offset some of these benefits, manifesting as a decline in left ventricular ejection fraction (LVEF). Patients receiving anthracycline-based chemotherapy followed by trastuzumab are at risk for CIC. Previous research evaluating whether clinical biomarkers predict cardiotoxicity has been inconsistent. Recently, angiotensin II type 1 receptor (ATR1) and endothelin 1 (ET1) have been shown to play a role in breast tumor growth. We evaluated ATR1 and ET1 expression in breast cancer tissue and its association with CIC. A total of 33 paraffin-embedded breast tissue specimens from women with breast cancer treated with anthracycline-based chemotherapy and trastuzumab were analyzed by immunohistochemistry (IHC) and qRT-PCR. We found that ET1 expression was increased in patients with an LVEF ≤ 50% (
Language	English
Publishing date	2022-06-20
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2662592-1
ISSN	2077-0383
ISSN	2077-0383
DOI	10.3390/jcm11123547
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Establishing an Ehlers-Danlos Syndrome Clinic: Lessons Learned.

Knight, Dacre R T / Confiado, Sunnie M / Bruno, Katelyn A / Fairweather, DeLisa / Seymour-Sonnier, Andrea M / Jain, Angita / Gehin, Jessica M / Whelan, Emily R / Culberson, Joshua H / Munipalli, Bala / Dawson, Nancy L / Rozen, Todd D / Wick, Joseph J / Kotha, Archana

SN comprehensive clinical medicine

2022 Volume 4, Issue 1, Page(s) 138

Abstract: In a large academic medical center, patient requests from the community and internal referrals for evaluation of suspected hypermobility conditions were being denied consultation because services specific to this condition were not available. We ... ...

Abstract	In a large academic medical center, patient requests from the community and internal referrals for evaluation of suspected hypermobility conditions were being denied consultation because services specific to this condition were not available. We identified this gap and developed a comprehensive evaluation for this unique patient population. The objective of this paper is to demonstrate a solution for improving outcomes in a neglected patient population by establishing an innovative outpatient clinic specifically tailored for patients with EDS. We describe the lessons learned on establishing a specialty clinic for treating patients with hypermobility syndromes including hypermobile Ehlers-Danlos syndrome (
Language	English
Publishing date	2022-07-05
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2947211-8
ISSN	2523-8973 ; 2523-8973
ISSN (online)	2523-8973
ISSN	2523-8973
DOI	10.1007/s42399-022-01218-w
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: Sex differences in left-ventricular strain in a murine model of coxsackievirus B3 myocarditis.

Di Florio, Damian N / Macomb, Logan P / Giresi, Presley G / Beetler, Danielle J / Bonvie-Hill, Natalie E / Shapiro, Katie A / Naser, Abdel-Rahman N / Khatib, Sami / Whelan, Emily R / Weigel, Gabriel J / Edenfield, Brandy H / Balamurugan, Varsini / Burris, Sarah K / Rich, Laurie J / Bruno, Katelyn A / Cooper, Leslie T / McLeod, Chris J / Yamani, Mohamad H / Fairweather, DeLisa

iScience

2023 Volume 26, Issue 12, Page(s) 108493

Abstract: Myocarditis is typically caused by viral infections, but most cases are thought to be subclinical. Echocardiography is often used for initial assessment of myocarditis patients but is poor at detecting subtle changes in cardiac dysfunction. Cardiac ... ...

Abstract	Myocarditis is typically caused by viral infections, but most cases are thought to be subclinical. Echocardiography is often used for initial assessment of myocarditis patients but is poor at detecting subtle changes in cardiac dysfunction. Cardiac strain, such as global longitudinal strain (GLS) and global circumferential strain (GCS), represents an increasingly used set of measurements which can detect these subtle changes. Using a murine model of coxsackievirus B3 myocarditis, we characterized functional changes in the heart using echocardiography during myocarditis and by sex. We found that 2D GLS, 4D mode, and 4D strains detected a significant reduction in ejection fraction and GLS during myocarditis compared to baseline and in males compared to females. Furthermore, worse GLS correlated to increased levels of CD45
Language	English
Publishing date	2023-11-20
Publishing country	United States
Document type	Journal Article
ISSN	2589-0042
ISSN (online)	2589-0042
DOI	10.1016/j.isci.2023.108493
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Trpc6 Promotes Doxorubicin-Induced Cardiomyopathy in Male Mice With Pleiotropic Differences Between Males and Females.

Frontiers in cardiovascular medicine

2022 Volume 8, Page(s) 757784

Abstract: Background: ...

Abstract	Background:
Language	English
Publishing date	2022-01-13
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2781496-8
ISSN	2297-055X
ISSN	2297-055X
DOI	10.3389/fcvm.2021.757784
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Reconstituted Extracellular Vesicles from Human Platelets Decrease Viral Myocarditis in Mice.

Beetler, Danielle J / Bruno, Katelyn A / Watkins, Molly M / Xu, Vivian / Chekuri, Isha / Giresi, Presley / Di Florio, Damian N / Whelan, Emily R / Edenfield, Brandy H / Walker, Sierra A / Morales-Lara, Andrea C / Hill, Anneliese R / Jain, Angita / Auda, Matthew E / Macomb, Logan P / Shapiro, Kathryn A / Keegan, Kevin C / Wolfram, Joy / Behfar, Atta /

Stalboerger, Paul G / Terzic, Andre / Farres, Houssam / Cooper, Leslie T / Fairweather, DeLisa

Small (Weinheim an der Bergstrasse, Germany)

2023 Volume 19, Issue 49, Page(s) e2303317

Abstract: Patients with viral myocarditis are at risk of sudden death and may progress to dilated cardiomyopathy (DCM). Currently, no disease-specific therapies exist to treat viral myocarditis. Here it is examined whether reconstituted, lyophilized extracellular ... ...

Abstract	Patients with viral myocarditis are at risk of sudden death and may progress to dilated cardiomyopathy (DCM). Currently, no disease-specific therapies exist to treat viral myocarditis. Here it is examined whether reconstituted, lyophilized extracellular vesicles (EVs) from platelets from healthy men and women reduce acute or chronic myocarditis in male mice. Human-platelet-derived EVs (PEV) do not cause toxicity, damage, or inflammation in naïve mice. PEV administered during the innate immune response significantly reduces myocarditis with fewer epidermal growth factor (EGF)-like module-containing mucin-like hormone receptor-like 1 (F4/80) macrophages, T cells (cluster of differentiation molecules 4 and 8, CD4 and CD8), and mast cells, and improved cardiac function. Innate immune mediators known to increase myocarditis are decreased by innate PEV treatment including Toll-like receptor (TLR)4 and complement. PEV also significantly reduces perivascular fibrosis and remodeling including interleukin 1 beta (IL-1β), transforming growth factor-beta 1, matrix metalloproteinase, collagen genes, and mast cell degranulation. PEV given at days 7-9 after infection reduces myocarditis and improves cardiac function. MicroRNA (miR) sequencing reveals that PEV contains miRs that decrease viral replication, TLR4 signaling, and T-cell activation. These data show that EVs from the platelets of healthy individuals can significantly reduce myocarditis and improve cardiac function.
MeSH term(s)	Humans ; Mice ; Male ; Female ; Animals ; Myocarditis ; Myocardium/metabolism ; Cardiomyopathy, Dilated/metabolism ; Immunity, Innate ; Macrophages/metabolism
Language	English
Publishing date	2023-08-23
Publishing country	Germany
Document type	Journal Article
ZDB-ID	2168935-0
ISSN	1613-6829 ; 1613-6810
ISSN (online)	1613-6829
ISSN	1613-6810
DOI	10.1002/smll.202303317
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: Sex-Specific Effects of Plastic Caging in Murine Viral Myocarditis.

Bruno, Katelyn A / Macomb, Logan P / Morales-Lara, A Carolina / Mathews, Jessica E / Frisancho, J Augusto / Yang, Alex L / Di Florio, Damian N / Edenfield, Brandy H / Whelan, Emily R / Salomon, Gary R / Hill, Anneliese R / Hewa-Rahinduwage, Chathuranga C / Scott, Ashley J / Greyner, Henry D / Molina, Frank A / Greenaway, Merci S / Cooper, George M / Fairweather, DeLisa

International journal of molecular sciences

2021 Volume 22, Issue 16

Abstract: Background: Myocarditis is an inflammatory heart disease caused by viral infections that can lead to heart failure, and occurs more often in men than women. Since animal studies have shown that myocarditis is influenced by sex hormones, we hypothesized ... ...

Abstract	Background: Myocarditis is an inflammatory heart disease caused by viral infections that can lead to heart failure, and occurs more often in men than women. Since animal studies have shown that myocarditis is influenced by sex hormones, we hypothesized that endocrine disruptors, which interfere with natural hormones, may play a role in the progression of the disease. The human population is exposed to the endocrine disruptor bisphenol A (BPA) from plastics, such as water bottles and plastic food containers. Methods: Male and female adult BALB/c mice were housed in plastic versus glass caging, or exposed to BPA in drinking water versus control water. Myocarditis was induced with coxsackievirus B3 on day 0, and the endpoints were assessed on day 10 post infection. Results: We found that male BALB/c mice that were exposed to plastic caging had increased myocarditis due to complement activation and elevated numbers of macrophages and neutrophils, whereas females had elevated mast cell activation and fibrosis. Conclusions: These findings show that housing mice in traditional plastic caging increases viral myocarditis in males and females, but using sex-specific immune mechanisms.
MeSH term(s)	Animals ; Coxsackievirus Infections/complications ; Coxsackievirus Infections/virology ; Enterovirus B, Human/pathogenicity ; Female ; Housing, Animal/statistics & numerical data ; Male ; Mice ; Mice, Inbred BALB C ; Myocarditis/etiology ; Myocarditis/pathology ; Myocarditis/virology ; Plastics/adverse effects ; Sex Factors
Chemical Substances	Plastics
Language	English
Publishing date	2021-08-17
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms22168834
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis.

Senefeld, Jonathon W / Gorman, Ellen K / Johnson, Patrick W / Moir, M Erin / Klassen, Stephen A / Carter, Rickey E / Paneth, Nigel S / Sullivan, David J / Morkeberg, Olaf H / Wright, R Scott / Fairweather, DeLisa / Bruno, Katelyn A / Shoham, Shmuel / Bloch, Evan M / Focosi, Daniele / Henderson, Jeffrey P / Juskewitch, Justin E / Pirofski, Liise-Anne / Grossman, Brenda J /

Tobian, Aaron A R / Franchini, Massimo / Ganesh, Ravindra / Hurt, Ryan T / Kay, Neil E / Parikh, Sameer A / Baker, Sarah E / Buchholtz, Zachary A / Buras, Matthew R / Clayburn, Andrew J / Dennis, Joshua J / Diaz Soto, Juan C / Herasevich, Vitaly / Klompas, Allan M / Kunze, Katie L / Larson, Kathryn F / Mills, John R / Regimbal, Riley J / Ripoll, Juan G / Sexton, Matthew A / Shepherd, John R A / Stubbs, James R / Theel, Elitza S / van Buskirk, Camille M / van Helmond, Noud / Vogt, Matthew N P / Whelan, Emily R / Wiggins, Chad C / Winters, Jeffrey L / Casadevall, Arturo / Joyner, Michael J

Mayo Clinic proceedings. Innovations, quality & outcomes

2023 Volume 7, Issue 5, Page(s) 499–513

Abstract: Objective: To examine the association of COVID-19 convalescent plasma transfusion with mortality and the differences between subgroups in hospitalized patients with COVID-19.: Patients and methods: On October 26, 2022, a systematic search was ... ...

Abstract	Objective: To examine the association of COVID-19 convalescent plasma transfusion with mortality and the differences between subgroups in hospitalized patients with COVID-19. Patients and methods: On October 26, 2022, a systematic search was performed for clinical studies of COVID-19 convalescent plasma in the literature from January 1, 2020, to October 26, 2022. Randomized clinical trials and matched cohort studies investigating COVID-19 convalescent plasma transfusion compared with standard of care treatment or placebo among hospitalized patients with confirmed COVID-19 were included. The electronic search yielded 3841 unique records, of which 744 were considered for full-text screening. The selection process was performed independently by a panel of 5 reviewers. The study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Data were extracted by 5 independent reviewers in duplicate and pooled using an inverse-variance random effects model. The prespecified end point was all-cause mortality during hospitalization. Results: Thirty-nine randomized clinical trials enrolling 21,529 participants and 70 matched cohort studies enrolling 50,160 participants were included in the systematic review. Separate meta-analyses reported that transfusion of COVID-19 convalescent plasma was associated with a decrease in mortality compared with the control cohort for both randomized clinical trials (odds ratio [OR], 0.87; 95% CI, 0.76-1.00) and matched cohort studies (OR, 0.76; 95% CI, 0.66-0.88). The meta-analysis of subgroups revealed 2 important findings. First, treatment with convalescent plasma containing high antibody levels was associated with a decrease in mortality compared with convalescent plasma containing low antibody levels (OR, 0.85; 95% CI, 0.73 to 0.99). Second, earlier treatment with COVID-19 convalescent plasma was associated with a decrease in mortality compared with the later treatment cohort (OR, 0.63; 95% CI, 0.48 to 0.82). Conclusion: During COVID-19 convalescent plasma use was associated with a 13% reduced risk of mortality, implying a mortality benefit for hospitalized patients with COVID-19, particularly those treated with convalescent plasma containing high antibody levels treated earlier in the disease course.
Language	English
Publishing date	2023-10-10
Publishing country	Netherlands
Document type	Journal Article
ISSN	2542-4548
ISSN (online)	2542-4548
DOI	10.1016/j.mayocpiqo.2023.09.001
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Mortality rates among hospitalized patients with COVID-19 treated with convalescent plasma: A Systematic review and meta-analysis

Senefeld, Jonathon / Gorman, Ellen K / Johnson, Patrick / Moir, M. Erin / Klassen, Stephen A / Carter, Rickey E / Paneth, Nigel S / Sullivan, David J / Morkeberg, Olaf H / Wright, R. Scott / Fairweather, DeLisa / Bruno, Katelyn A / Shoham, Shmuel / Bloch, Evan M / Focosi, Daniele / Henderson, Jeffrey P / Juskewitch, Justin E / Pirofski, Liise-anne / Grossman, Brenda J /

Tobian, Aaron AR / Franchini, Massimo / Ganesh, Ravindra / Hurt, Ryan T / Kay, Neil E / Parikh, Sameer A / Baker, Sarah E / Buchholtz, Zachary A / Buras, Matthew R / Clayburn, Andrew J / Dennis, Joshua J / Diaz Soto, Juan C / Herasevich, Vitaly / Klompas, Allan M / Kunze, Katie L / Larson, Kathryn F / Mills, John R / Regimbal, Riley J / Ripoll, Juan G / Sexton, Matthew A / Shepherd, John RA / Stubbs, James R / Theel, Elitza S / van Buskirk, Camille M / van Helmond, Noud / Vogt, Matthew NP / Whelan, Emily R / Wiggins, Chad C / Winters, Jeffrey L / Casadevall, Arturo / Joyner, Michael J

medRxiv

Abstract: Abstract IMPORTANCE. Many hospitalized patients with COVID-19 have been treated with convalescent plasma. However, it is uncertain whether this therapy lowers mortality and if so, if the mortality benefit is larger among specific subgroups, such as ... ...

Abstract	Abstract IMPORTANCE. Many hospitalized patients with COVID-19 have been treated with convalescent plasma. However, it is uncertain whether this therapy lowers mortality and if so, if the mortality benefit is larger among specific subgroups, such as recipients of plasma with high antibody content and patients treated early in the disease course. OBJECTIVE. To examine the association of COVID-19 convalescent plasma transfusion with mortality and the differences between subgroups in hospitalized patients with COVID-19. DATA SOURCES. On October 26, 2022, a systematic search was performed for clinical studies of COVID-19 convalescent plasma in the literature. STUDY SELECTION. Randomized clinical trials and matched cohort studies investigating COVID-19 convalescent plasma transfusion compared with standard of care treatment or placebo among hospitalized patients with confirmed COVID-19 were included. The electronic search yielded 3,841 unique records, of which 744 were considered for full-text screening. The selection process was performed independently by a panel of five reviewers. DATA EXTRACTION AND SYNTHESIS. The study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Data were extracted by 5 independent reviewers in duplicate and pooled using inverse-variance random-effects model. MAIN OUTCOMES AND MEASURES. Prespecified end point was all-cause mortality during hospitalization. RESULTS. Thirty-nine randomized clinical trials enrolling 21,529 participants and 70 matched cohort studies enrolling 50,160 participants were included in the systematic review. Separate meta-analyses demonstrated that transfusion of COVID-19 convalescent plasma was associated with a significant decrease in mortality compared with the control cohort for both randomized clinical trials (odds ratio (OR), 0.87 [95% CI, 0.76-1.00]) and matched cohort studies (OR, 0.77 [95% CI, 0.64-0.94]). Meta-analysis of subgroups revealed two important findings. First, treatment with convalescent plasma containing high antibody levels was associated with a decrease in mortality compared to convalescent plasma containing low antibody levels (OR, 0.85 [95% CI, 0.73 to 0.99]). Second, earlier treatment with COVID-19 convalescent plasma was associated with a significant decrease in mortality compared with the later treatment cohort (OR, 0.63 [95% CI, 0.48 to 0.82]). CONCLUSIONS AND RELEVANCE. COVID-19 convalescent plasma use was associated with a 13% reduced risk in mortality, implying a mortality benefit for hospitalized patients with COVID-19, particularly those treated with convalescent plasma containing high antibody levels treated earlier in the disease course.
Keywords	covid19
Language	English
Publishing date	2023-01-12
Publisher	Cold Spring Harbor Laboratory Press
Document type	Article ; Online
DOI	10.1101/2023.01.11.23284347
Database	COVID19

Full text online

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

Kategorien

Inter-library loan at ZB MED